Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Borel

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Therapie|December 22, 2011
[How to optimize the carrying out and the development of post-registration studies]Thomas Borel, Chrystel Jouan-Flahault,
Sante Publique (Vandoeuvre-Les-Nancy, France)|May 30, 2009
[Do economic actors have a role to play in public health decision - making and defining strategic directions?]Thomas Borel, Philippe Lecorps, Claude Michaud
Therapie|July 10, 2016
[Not Available]Jean-Marie Goehrs, Thomas Borel, Dominique Costagliola, et al.
Therapie|November 1, 2012
[Not Available]Jean-Marie Goehrs, Thomas Borel, Dominique Costagliola, et al.
Therapie|May 31, 2021
France's competitiveness in global pharmaceutical research: The situation is improvingAnne d'Andon, Ariane Galaup, Cecile Fabron, et al.
Therapie|November 25, 2018
Clinical added value of drugs: An empirical survey of French transparency committee opinionsBruno Detournay, Thomas Borel, Matthieu Trancart, et al.
Therapie|May 14, 2018
[Attractiveness of France for international clinical research: 8th survey conducted by Leem (French association for pharmaceutical companies)]Ariane Galaup, Philippe Barthélémy, Brigitte Pouletty-Lefebvre, et al.
Therapie|July 10, 2016
[Not Available]Jean-François Dhainaut, François Bassompierre, Christophe Misse, et al.
Therapie|March 10, 2015
What strategy should France implement for H2020?Jean-François Dhainaut, Vincent Diebolt, Brigitte Pouletty-Lefèbvre, et al.
Therapie|August 29, 2013
Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012Benoît Dervaux, Eric Baseilhac, Jean-Yves Fagon, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Therapie|December 22, 2011
[How to optimize the carrying out and the development of post-registration studies]Thomas Borel, Chrystel Jouan-Flahault,
Sante Publique (Vandoeuvre-Les-Nancy, France)|May 30, 2009
[Do economic actors have a role to play in public health decision - making and defining strategic directions?]Thomas Borel, Philippe Lecorps, Claude Michaud
Therapie|July 10, 2016
[Not Available]Jean-Marie Goehrs, Thomas Borel, Dominique Costagliola, et al.
Therapie|November 1, 2012
[Not Available]Jean-Marie Goehrs, Thomas Borel, Dominique Costagliola, et al.
Therapie|May 31, 2021
France's competitiveness in global pharmaceutical research: The situation is improvingAnne d'Andon, Ariane Galaup, Cecile Fabron, et al.
Therapie|November 25, 2018
Clinical added value of drugs: An empirical survey of French transparency committee opinionsBruno Detournay, Thomas Borel, Matthieu Trancart, et al.
Therapie|May 14, 2018
[Attractiveness of France for international clinical research: 8th survey conducted by Leem (French association for pharmaceutical companies)]Ariane Galaup, Philippe Barthélémy, Brigitte Pouletty-Lefebvre, et al.
Therapie|July 10, 2016
[Not Available]Jean-François Dhainaut, François Bassompierre, Christophe Misse, et al.
Therapie|March 10, 2015
What strategy should France implement for H2020?Jean-François Dhainaut, Vincent Diebolt, Brigitte Pouletty-Lefèbvre, et al.
Therapie|August 29, 2013
Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012Benoît Dervaux, Eric Baseilhac, Jean-Yves Fagon, et al.
Pageof 2